Monographie - Amiodarone hydrochloride

Son güncelleme :
06/05/2024

Amiodarone hydrochloride

Kimyasal yapı

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Acrodarona	Ekvador
Amidovin	Türkiye
Amiocar	Arjantin, Peru
Amiodar	İtalya
Amiodaron	Almanya, İsveç, Norveç
Amiodarona	Arjantin, Ekvador, Kolombiya, Meksika, Peru, Şili
Amiodarone	Amerika Birleşik Devletleri, Avustralya, Büyük Britanya, İran, İtalya, Kanada, Lüksemburg, Yeni Zelanda
Amiohexal	Almanya
Amiokordin	Macaristan, Polonya, Romanya
Amiorit	Venezuela
Ancoron	Brezilya
Angoron	Yunanistan
Asulblan	Arjantin
Atlansil	Arjantin, Brezilya, Ekvador, Peru, Şili
Cardasol	Hindistan
Cardichek	Hindistan
Cardio	Mısır
Cirtrent	Meksika
Cordalin	Türkiye
Cordarex	Almanya
Cordarone	Amerika Birleşik Devletleri, Avustralya, Belçika, Birleşik Arap Emirlikleri, Büyük Britanya, Danimarka, Ekvador, Fas, Finlandiya, Fransa, Hollanda, İrlanda, İsveç, İsviçre, İtalya, İzlanda, Kolombiya, Lüksemburg, Macaristan, Malezya, Meksika, Norveç, Polonya, Portekiz, Şili, Suudi Arabistan, Tunus, Türkiye, Yeni Zelanda
Duron	Hindistan
Eudarona	Venezuela
Eurythmic	Hindistan
Farcodarone	Mısır
Ronecard	Mısır
Sedacoron	Avusturya, Polonya, Romanya, Suudi Arabistan, Tunus
Sedacorone	İran
Trangorex	İspanya, Venezuela

Kaynaklar : Amiodarone hydrochloride

	Tip	Yayın
200	Dergi	Korth-Bradley JM, Ludwig S, Callaghan C. Incompatibility of amiodarone hydrochloride and sodium bicarbonate injections. Am J Health-Syst Pharm 1995 ; 52: 2340.
205	Dergi	Strozyk WR, Williamson R, Thompson D. Incompatibility of amiodarone hydrochloride and evacuated glass bottles. Am J Health-Syst Pharm 1996 ; 53: 184.
242	Dergi	Campbell S, Nolan PE, Bliss M, Wood R, Mayersohn M. Stability of amiodarone hydrochloride in admixtures with other injectable drugs. Am J Hosp Pharm 1986 ; 43: 917-921.
295	Dergi	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
379	Dergi	Weir SJ, Szucs Myers VA, Bengtson KD, Ueda CT. Sorption of amiodarone to polyvinyl chloride infusion bags and administration sets. Am J Hosp Pharm 1985 ; 42: 2679-2683.
385	Dergi	Benedict MK, Roche VF, Banakar UV, Hilleman DE. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1117-1118.
647	Dergi	Pramar YV. Chemical stability of amiodarone hydrochloride in intravenous fluids. Int J Pharm Compound 1997 ; 1: 347-348.
925	Dergi	Dupuis LL, Trope A, Giesbrecht E, Wong B. Compatibility and stability of propafenone hydrochloride with five critical-care medications. Can J Hosp Pharm 1998 ; 51: 55-57.
1036	Dergi	Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041	Dergi	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1232	Dergi	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1508	Dergi	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1611	Dergi	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1712	Dergi	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Dergi	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Dergi	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1733	Dergi	Kopelent-Frank H, Schimper A. HPTLC-based stability assay for determination of amiodarone in intravenous admixtures. Pharmazie 1999 ; 54: 542-544.
1801	Dergi	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803	Dergi	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1963	Dergi	Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS. Compatibility of argatroban with selected cardiovascular agents. Am J Health-Syst Pharm 2004 ; 61: 2415-2418.
2090	Dergi	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Dergi	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Dergi	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2139	Dergi	Serrurier C, Chenot ED, Vigneron J, May I, Demor? B. Assessment of injectable drug’s administration in two intensive care units and determination of potential physico-chemical incompatibilities. EJHP Science 2006 ; 12,5: 96-99.
2146	Dergi	Trissel LA, Xu QA, Baker M. Drug compatibility with new polyolefin infusion solution containers. Am J Health-Syst Pharm 2006 ; 63: 2379-2382.
2247	Dergi	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Dergi	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Dergi	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2346	Dergi	Newland A.M, Mauro V.F, Alexander K.S. Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents Am J Health-Syst Pharm 2009 ; 66: 986-987.
3012	Dergi	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3134	Dergi	Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ; 21: 96-103.
3210	Dergi	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3212	Dergi	Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos. Enferm Intensiva 2011 ;22:78-82.
3216	Dergi	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Dergi	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3372	Dergi	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3379	Dergi	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3381	Dergi	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Gattlen L, Pannatier A. In vitro compatibility of various cardioactive drugs during simulated Y-site administration. EJHP 2013 ; 20:110-116.
3408	Dergi	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3463	Dergi	Eva Perez Juan, Maria Jos? Arévalo Rubert , Silvia Monica Amoros Cerda , Palau M.M, Nicolau B.R. Fármacos en perfusión continua en la unidad de cuidados intensivos: estudio de compatibilidad. Nursing 2011 ; 29 :62-6
3464	Dergi	Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau. Compatibilidad física de la amiodarona en perfusión continua Enferm Clin 2011 21:25-29.
3465	Dergi	E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ;21:96-103.
3466	Dergi	B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos Enferm Intensiva 2011 ;22:78-82.
3524	Laboratuar	Amiodarone hydrochloride (Cordarone®) - Summary of Product Characteristics. Sanofi 2013
3539	Laboratuar	Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013
3540	Laboratuar	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3766	Dergi	Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Dergi	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3823	Dergi	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l’unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3824	Dergi	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Afiş	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Afiş	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Afiş	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3932	Laboratuar	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
3964	Dergi	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Dergi	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4119	Afiş	Marcoz N, Ing H, Sautter AM, Saadi JF, Roulin JF, Bonnabry P. Stabilité et compatibilité de solutions injectables d'amiodarone (Cordarone®) Hôpitaux Universitaire de Genève 2004
4130	Dergi	Koller AK, Krebs S, Dörje F. Untersuchungen zur Kompatibilität von Clonidin mit häufig eingesetzen Arzneimittel auf Intensivstationen. Pharmaceutics 2021 , 13, 21.
4145	Dergi	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4252	Dergi	Lardinois B, Dimitriou A, Delcave C, Jamart J, Bihin B, Soumoy L, Hecq JD, Galanti LM. Evaluation of the Physicochemical Stability of Amiodarone Hydrochloride in Syringes for the Intensive Care Unit. Int J Pharm Compound 2019 ;23,2:163-166
4319	Dergi	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4354	Afiş	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos lors d'administration en Y avec une sélection de médicaments injectables. GERPAC Congress 2019 2019
4371	Dergi	Mediavilla MM, Molina A, Navarro L, Grau L, Pujol MD, Cardenete J, Cardona D, Riera P. Physicochemical Compatibility of Amiodarone with Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition 2018
4411	Dergi	Wilder A.G, Foushee J.A, Fox L.M, Navalle J, Wright A.M, Greer M.A. Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions. Int J Pharm Compound 2020 ;24,3:238-241.
4434	Dergi	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4491	Dergi	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020
4506	Dergi	Griffith S, Stapleton E, Padilla S, Mruk A, Thomas C. Physical compatibility of milrinone 1 mg/mL with select cardiovascular medications during simulated Y-site administration. Am J Health-Syst Pharm 2020 ;77,23:1938-1940.
4528	Dergi	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Dergi	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratuar	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4651	Dergi	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4655	Dergi	Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33
4698	Dergi	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022
4742	Dergi	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Mentions Légales